Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
In development: Guidance, quality standards and advice
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (9)
Type
Type
Guidance (412)
NICE advice (1)
Quality standard (11)
Guidance programme
Guidance programme
Clinical guidelines (29)
Diagnostics guidance (7)
Health technology evaluations (16)
Highly specialised technologies guidance (9)
Interventional procedures guidance (21)
Medical technologies guidance (13)
NICE guidelines (32)
Public health guidelines (1)
Technology appraisal guidance (325)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 301 to 325 of 424
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating primary advanced or recurrent endometrial cancer ID6381
Technology appraisal guidance
16 April 2025
Pembrolizumab with stereotactic body radiotherapy for treating unresected stage 1 or 2 non-small-cell lung cancer [ID6149]
Technology appraisal guidance
TBC
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]
Technology appraisal guidance
TBC
Pemigatinib for treating myeloid or lymphoid neoplasms with a FGFR1 rearrangement [ID6172]
Technology appraisal guidance
TBC
Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]
Technology appraisal guidance
TBC
PillCam COLON 2 for investigation of the colon through direct visualisation
Diagnostics guidance
17 July 2025
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
Technology appraisal guidance
TBC
Pirtobrutinib for treating relapsed or refractory mantle cell lymphoma [ID3975]
Technology appraisal guidance
TBC
Pirtobrutinib for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID6397]
Technology appraisal guidance
TBC
Pitolisant for treating narcolepsy in children and young people 6 to 17 years ID6353
Technology appraisal guidance
TBC
Pneumonia QS update
Quality standard
14 August 2025
Pneumonia: diagnosis and management (update)
NICE guideline
TBC
Port Delivery System with ranibizumab for treating wet age-related macular degeneration [ID3983]
Technology appraisal guidance
TBC
Pralsetinib for thyroid cancer [ID4018]
Technology appraisal guidance
TBC
Pulsed field ablation for atrial fibrillation
Interventional procedures guidance
9 July 2025
Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]
Technology appraisal guidance
15 November 2017
Rehabilitation for chronic neurological disorders including acquired brain injury
NICE guideline
16 July 2025
Relugolix–estradiol–norethisterone for treating symptoms of endometriosis [ID3982]
Technology appraisal guidance
TBC
Renal cell carcinoma Pathways Pilot [ID6186]
Technology appraisal guidance
TBC
Repotrectinib for treating ROS1-positive advanced non-small-cell lung cancer [ID6277]
Technology appraisal guidance
TBC
Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer TSID 12007
Technology appraisal guidance
TBC
Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women (ID1307)
Technology appraisal guidance
TBC
Ribociclib with an aromatase inhibitor for adjuvant treatment of hormone receptor-positive, HER2-negative early breast cancer [ID6153]
Technology appraisal guidance
18 June 2025
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]
Technology appraisal guidance
TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Technology appraisal guidance
TBC
Previous page
1
…
11
12
Current page
13
14
15
…
17
Page
13
of
17
Next page
Results per page
10
25
50
All
Back to top